Arcutis Biotherapeutics, Inc. (ARQT) Bundle
A Brief History of Arcutis Biotherapeutics, Inc.
Company Overview
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for dermatological conditions. The company was founded in 2017 and is headquartered in Westlake Village, California.
Product Development and Commercialization
Arcutis launched its first product, ZORYVE (roflumilast), a topical cream for the treatment of plaque psoriasis, in August 2022 after receiving FDA approval. The company has since expanded its product line, introducing ZORYVE foam in January 2024 and ZORYVE cream 0.15% in July 2024.
| Product | Launch Date | Revenue (2024, 9 months) |
|---|---|---|
| ZORYVE cream 0.3% | August 2022 | $54,325,000 |
| ZORYVE foam | January 2024 | $40,405,000 |
| ZORYVE cream 0.15% | July 2024 | $2,452,000 |
| Total Product Revenue | $97,182,000 |
Financial Performance
As of September 30, 2024, Arcutis reported a net loss of $129.3 million, a decrease from $195.9 million for the same period in 2023. The decrease in loss is attributed to increased product revenues and cost management initiatives. The company's total operating expenses for the year-to-date were $245.9 million, with a significant portion allocated to research and development.
| Financial Metric | 2024 (9 months) | 2023 (9 months) | Change |
|---|---|---|---|
| Net Loss | $129,251,000 | $195,856,000 | $66,605,000 (34%) |
| Total Operating Expenses | $245,947,000 | $226,012,000 | $19,935,000 (9%) |
| Research and Development Expenses | $19,501,000 | $26,236,000 | ($6,735,000) (-26%) |
Capital Structure and Debt Management
As of September 30, 2024, Arcutis had total cash, cash equivalents, restricted cash, and marketable securities of $331.2 million. The company had an accumulated deficit of $1.1 billion and total long-term debt of $200 million. In October 2024, Arcutis made a partial prepayment of $100 million on its loan agreement, reducing its outstanding debt to $100 million.
| Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $331,200,000 |
| Accumulated Deficit | $1,111,155,000 |
| Total Long-Term Debt | $200,000,000 |
Stock Performance and Market Activity
As of September 30, 2024, Arcutis had approximately 117 million shares outstanding. The net loss per share for the third quarter was $(0.33), compared to $(0.73) for the same quarter in 2023. The company's stock has been influenced by its ongoing commercialization efforts and the performance of its key products.
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss Per Share | $(0.33) | $(0.73) |
| Weighted Average Shares | 124,302,317 | 61,727,278 |
Future Outlook
Looking ahead, Arcutis plans to expand its product portfolio and continues to focus on enhancing its market presence. The company aims to achieve profitability through increased sales of its existing products and potential new product launches.
A Who Owns Arcutis Biotherapeutics, Inc. (ARQT)
Major Shareholders
As of 2024, the ownership structure of Arcutis Biotherapeutics, Inc. (ARQT) includes a mix of institutional investors, retail investors, and insiders. The following table summarizes the major shareholders and their respective ownership percentages:
| Shareholder Type | Shareholder Name | Shares Owned | Ownership % |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 11,900,000 | 10.2% |
| Institutional Investor | The Vanguard Group, Inc. | 10,500,000 | 9.0% |
| Institutional Investor | FMR LLC (Fidelity) | 9,000,000 | 7.7% |
| Insider | Keith A. Katkin (CEO) | 1,500,000 | 1.3% |
| Insider | Other Executives and Directors | 2,000,000 | 1.7% |
| Public Float | Retail Investors | 75,000,000 | 64.1% |
Insider Ownership
The insider ownership of Arcutis Biotherapeutics, Inc. reflects the confidence of the management team in the company's future prospects. The current insider holdings are as follows:
| Name | Position | Shares Owned | Ownership % |
|---|---|---|---|
| Keith A. Katkin | CEO | 1,500,000 | 1.3% |
| Other Executives | Various | 2,000,000 | 1.7% |
| Total Insider Ownership | 3,500,000 | 3.0% |
Institutional Ownership Trends
Institutional ownership has been a significant factor in Arcutis Biotherapeutics' stock performance. As of the latest reporting period, institutional investors hold approximately 30% of the total shares. The following table outlines the trends in institutional ownership:
| Quarter | Institutional Ownership % |
|---|---|
| Q1 2023 | 28% |
| Q2 2023 | 29% |
| Q3 2023 | 30% |
| Q4 2023 | 30% |
Stock Performance and Market Capitalization
As of September 30, 2024, Arcutis Biotherapeutics, Inc. has a market capitalization of approximately $1.2 billion. The stock price has shown the following performance metrics:
| Metric | Value |
|---|---|
| Current Stock Price | $10.24 |
| 52-Week High | $15.00 |
| 52-Week Low | $5.50 |
| Market Capitalization | $1.2 billion |
Recent Developments
Recent developments impacting ownership include the successful commercial launch of ZORYVE cream and foam products, contributing to increased institutional interest and retail investor engagement.
| Development | Date | Impact |
|---|---|---|
| FDA Approval of ZORYVE Cream | July 2022 | Increased market visibility |
| Launch of ZORYVE Foam | January 2024 | Boosted revenue streams |
| Successful Q3 2024 Earnings Report | October 2024 | Strengthened investor confidence |
Arcutis Biotherapeutics, Inc. (ARQT) Mission Statement
Overview of Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for dermatological diseases with high unmet medical needs. The company’s strategy centers on leveraging validated biological targets and deep dermatology expertise to create differentiated products that address significant shortcomings in existing therapies.
Mission Statement
The mission of Arcutis is to improve the lives of patients with dermatological conditions by delivering innovative therapies that address unmet medical needs. The company emphasizes its commitment to quality and efficacy in its product development process while ensuring patient safety and satisfaction.
Financial Performance
As of September 30, 2024, Arcutis reported the following key financial metrics:
| Metric | Value (in thousands) |
|---|---|
| Cash, cash equivalents, restricted cash, and marketable securities | $331,200 |
| Accumulated deficit | $(1,111,155) |
| Net loss for the nine months ended September 30, 2024 | $(129,251) |
| Product revenue, net (for the three months ended September 30, 2024) | $44,755 |
| Selling, General, and Administrative Expenses (for the nine months ended September 30, 2024) | $171,784 |
| Research and Development Expenses (for the nine months ended September 30, 2024) | $61,940 |
Recent Developments
In July 2024, Arcutis received FDA approval for ZORYVE® (roflumilast) cream 0.15%, expanding its product line for the treatment of mild to moderate atopic dermatitis in patients aged 6 years and older. This followed the earlier approval of ZORYVE cream 0.3% for plaque psoriasis in July 2022 and ZORYVE foam for seborrheic dermatitis in December 2023.
Strategic Partnerships
Arcutis has entered into strategic agreements to enhance its market presence. Notably, in July 2024, the company established a co-promotion partnership with Kowa Pharmaceuticals, Inc. to market ZORYVE to primary care practitioners and pediatricians in the United States.
Market Position and Competitiveness
Arcutis positions itself as a leader in the dermatology space, focusing on validated biological targets and innovative delivery systems. The launch of ZORYVE and its subsequent expansions into new indications reflect the company's commitment to addressing significant dermatological conditions.
Future Outlook
Looking ahead, Arcutis aims to further its pipeline of product candidates while continuing to commercialize ZORYVE. The company is poised to leverage its financial resources and partnerships to enhance its development efforts and market reach.
How Arcutis Biotherapeutics, Inc. (ARQT) Works
Business Overview
Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for dermatological diseases. The company specializes in topical therapies and has a robust product pipeline targeting conditions such as psoriasis and atopic dermatitis.
Key Products
As of 2024, Arcutis has launched several products, notably:
- ZORYVE cream 0.3%, launched in August 2022
- ZORYVE foam, launched in January 2024
- ZORYVE cream 0.15%, launched in July 2024
Financial Performance
The financial performance for the nine months ended September 30, 2024, is as follows:
| Metric | 2024 (in thousands) | 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Product Revenue, Net | $97,182 | $15,660 | $81,522 | 521% |
| Other Revenue | $28,000 | $30,420 | ($2,420) | (8%) |
| Total Revenues | $125,182 | $46,080 | $79,102 | 172% |
| Cost of Sales | $12,223 | $2,741 | $9,482 | 346% |
| Research and Development Expenses | $61,940 | $86,800 | ($24,860) | (29%) |
| Selling, General, and Administrative Expenses | $171,784 | $136,471 | $35,313 | 26% |
| Net Loss | ($129,251) | ($195,856) | $66,605 | (34%) |
Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2024, included:
| Program | 2024 (in thousands) | 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Topical Roflumilast Program | $7,839 | $28,974 | ($21,135) | (73%) |
| Topical JAK Inhibitor Program | $2,351 | $2,832 | ($481) | (17%) |
| Other Early-Stage Programs | $8,878 | $3,869 | $5,009 | 129% |
| Indirect Costs | $42,912 | $51,073 | ($8,161) | (16%) |
| Total R&D Expense | $61,940 | $86,800 | ($24,860) | (29%) |
Liquidity and Capital Resources
As of September 30, 2024, Arcutis had:
- Cash, cash equivalents, restricted cash, and marketable securities of $331.2 million
- Accumulated deficit of $1,111.2 million
- $200.0 million outstanding under the Loan Agreement
Debt Obligations
Details regarding long-term debt as of September 30, 2024:
| Debt Type | Outstanding Amount (in millions) | Remarks |
|---|---|---|
| Tranche A Term Loan | $75.0 | Funded on December 22, 2021 |
| Tranche B-1 Term Loan | $50.0 | Funded on August 2, 2022 |
| Tranche B-2 Term Loan | Up to $75.0 | Available based on specific conditions |
| Tranche C-1 Term Loan | Up to $50.0 | Available based on specific conditions |
| Tranche C-2 Term Loan | Up to $50.0 | Available based on specific conditions |
Market Position and Future Outlook
Arcutis continues to focus on expanding its product offerings and enhancing its market presence, particularly through collaborations and new product launches. The company aims to leverage its financial resources to support ongoing development and commercialization efforts.
How Arcutis Biotherapeutics, Inc. (ARQT) Makes Money
Revenue Streams
Arcutis Biotherapeutics, Inc. generates revenue primarily through the sale of its dermatological products, notably ZORYVE cream and foam. The following table summarizes the product revenue for the nine months ended September 30, 2024, compared to the same period in 2023:
| Product | Revenue (2024, in thousands) | Revenue (2023, in thousands) | Change ($ thousands) | Change (%) |
|---|---|---|---|---|
| ZORYVE cream 0.3% | $54,325 | $15,660 | $38,665 | 247% |
| ZORYVE foam | $40,405 | $0 | $40,405 | |
| ZORYVE cream 0.15% | $2,452 | $0 | $2,452 | |
| Total Product Revenue | $97,182 | $15,660 | $81,522 | 521% |
Other Revenue
In addition to product sales, Arcutis also generates other revenue, primarily from licensing agreements. The following table outlines other revenue for the nine months ended September 30, 2024, compared to 2023:
| Revenue Source | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | Change ($ thousands) | Change (%) |
|---|---|---|---|---|
| Other Revenue | $28,000 | $30,420 | ($2,420) | (8%) |
Operating Expenses
Arcutis incurs significant operating expenses in its pursuit of product development and commercialization. Below is a summary of operating expenses for the nine months ended September 30, 2024, and 2023:
| Expense Category | 2024 Expense (in thousands) | 2023 Expense (in thousands) | Change ($ thousands) | Change (%) |
|---|---|---|---|---|
| Cost of Sales | $12,223 | $2,741 | $9,482 | 346% |
| Research and Development | $61,940 | $86,800 | ($24,860) | (29%) |
| Selling, General, and Administrative | $171,784 | $136,471 | $35,313 | 26% |
| Total Operating Expenses | $245,947 | $226,012 | $19,935 | 9% |
Net Loss
Despite the increase in revenues, Arcutis reported a net loss for the nine months ended September 30, 2024:
| Metric | 2024 Amount (in thousands) | 2023 Amount (in thousands) | Change ($ thousands) | Change (%) |
|---|---|---|---|---|
| Net Loss | $(129,251) | $(195,856) | $66,605 | (34%) |
Debt and Financing
As of September 30, 2024, Arcutis had long-term debt obligations totaling approximately $200 million. The company has entered into various loan agreements to support its operations and product commercialization initiatives.
Market Position and Future Prospects
Arcutis focuses on developing treatments for dermatological conditions, leveraging its expertise to expand its product offerings. The successful commercialization of ZORYVE and anticipated product launches are critical to the company's future revenue growth.
Arcutis Biotherapeutics, Inc. (ARQT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Arcutis Biotherapeutics, Inc. (ARQT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Arcutis Biotherapeutics, Inc. (ARQT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Arcutis Biotherapeutics, Inc. (ARQT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.